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ABSTRACT
Lymphatic vasculature plays a crucial role in the immune response, enabling transport of dendritic cells (DCs)
and antigens (Ags) into the lymph nodes. Unfortunately, the lymphatic system has also a negative role in the
progression of cancer diseases, by facilitating the metastatic spread of many carcinomas to the draining
lymph nodes. The lymphatics can promote antitumor immune response as well as tumor tolerance. Here, we
review the role of lymphatic endothelial cells (LECs) in tumor progression and immunity and mechanism of
action in the newest anti-lymphatic therapies, including photodynamic therapy (PDT).
Abbreviations: Ags, antigens; AKT, protein kinase B; AMD, age macular degeneration; Ang1/2, angiopoietin-1/2;
APCs, antigen-presenting cells; CCL5/19/21, chemokine (C–C motif) ligand 5/19/21; CCR4/5/l7, C–C chemokine
receptor type 4/5/7; COX-2, cyclooxygenase-2; CD, cluster of differentiation; DCs, dendritic cells; ERK1/2, extracellu-
lar-signal-regulated kinases; HIF-1, hypoxia-inducible transcription factor; ICAM-1, intercellular adhesion molecule 1;
IRES, internal ribosome entry site; LECs, lymphatic endothelial cells; LEN, lenalidomide; MDSCs, myeloid-derived
suppressor cells; MHC, major histocompatibility complex; mTOR, mammalian target of rapamycin kinase; PDT, pho-
todynamic therapy; PGE2, prostaglandin E2; PROX-1, prospero homeobox 1; SMCs, smooth muscle cells; SOX18,
SRY-related HMG-box; STAT3, signal transducer and activator of transcription 3; TAMs, tumor-associated macro-
phages; TCM, tumor-conditioned media; Tie2, angiopoietin receptors; TGFBIp, transforming growth factor-
b-induced protein; TGF-b, transforming growth factor b; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor
receptor 1; VEGF-A/VEGF-C/VEGF-D, vascular endothelial growth factor C/D; VEGFR, vascular endothelial growth
factor receptor
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Introduction
One of the main causes of cancer evasion is the ability of tumor
cells to spread to local and distant tissues and organs. Therefore,
for several decades, a major focus of cancer research was to under-
stand the mechanisms which unlock the ability of tumor cells to
formmetastases. Many studies showed that the lymphatic develop-
ment can be re-activated during tumor lymphangiogenesis and, as
it was widely reviewed before, the tumor lymphangiogenesis
strongly depends on vascular endothelial growth factor C/D
(VEGF-C/D) and vascular endothelial growth factor receptor 3
(VEGFR-3) pathway.1 In lymphangiogenesis, the pivotal role is
also played by the SRY-related HMG-box (SOX18), which through
activation of prospero homeobox 1 (Prox-1) transcription, induces
expression of lymphatic-speciﬁc genes, e.g. podoplanin. 2
Recent research has been focused on uncovering the active role
of lymphatic endothelium in tumor cells transport andmodulation
of antitumor immune response.3 The communication between
immune system and tumor is initiated with blind-ended capillaries
of afferent lymphatics that merge into larger collecting vessels and
connect tissue with lymph nodes. This lymphatic link between
tumor and the distant microenvironment is associated with ﬂow of
tumor antigens (Ags), cytokines and enzymes but is also crucial for
the progression and dissemination of tumor cells. In face of the dis-
covery of several key lymphatic-speciﬁc molecular markers, the
number of studies on lymphatic biology has been recently aug-
mented. Therefore, we review the role of lymphatic endothelial cells
(LECs) in tumor progression and immunity as well as the require-
ments for tumor cells to enter initial afferent lymphatic vessels. We
discuss the newest achievements in anti-lymphatic therapies
underlying some innovative treatments such as photodynamic
therapy (PDT).
Structure and function of lymphatic vessels
Normal tissue ﬂuid homeostasis in the human body is depen-
dent on mutual reinforcing functions of blood and lymph
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vessels system. In contrast to blood vessels responsible for
delivery of oxygen, nutrients, hormones and cells to the body
tissues, lymphatic vessels are specialized in uptake of tissue
ﬂuid with macromolecules, microbes and other substances
from interstitial space.4
The lymphatic vessels are present in tissues that fre-
quently come in contact with foreign Ags, such as the skin
and mucous membranes. Moreover, lymphatic vessels are
found in all vascularized tissues, including recently discov-
ered central nervous system lymphatic vasculature, with
notable exception of bone marrow.5 Tissue ﬂuid ﬁrst enters
lymphatic capillaries, comprised of LECs organized in
highly permeable single-layered, blind-ended and thin-
walled sacs. LECs are attached to the extracellular matrix
through elastic anchoring ﬁlaments. These ﬁbrillin-stranded
structures protect vessels from collapse and stretch under
high-interstitial pressure. This leads to the opening of endo-
thelial ﬂaps, allowing ﬂuid and macromolecules to enter the
vessel’s lumen.6 The lymph is further transferred to larger
pre-collector vessels that contain occasional valves, a base-
ment membrane and sparse coverage of smooth muscle cells
(SMCs). The pre-collectors converge into the lymphatic col-
lecting vessels, with LECs forming continuous “zipper-like”
junctions, surrounded by a basement membrane and sup-
ported by incessant layer of SMCs. The lymph ﬂow is
achieved by SMCs contractility, vasomotion and the activity
of surrounding skeletal muscles. The bileaﬂet valves in col-
lecting vessels prevent the backﬂow of lymph.7 The collec-
tors pass the lymph to the lymph nodes and further to
lymphatic trunks and right lymphatic and thoracic ducts,
where lymph is eventually drained back into the venous cir-
culation at the venous angles.1 Therefore, the central func-
tion of lymphatic vascular system is to sustain tissue-ﬂuid
homeostasis. Additionally, lacteal lymphatic vessels absorb
and transport fat soluble vitamins and dietary fat, such as
chylomicrons, from the small intestine, bypassing the liver
that normally clear hydrophilic substances collected by
blood from the intestine. In addition, the lymphatic system
is essential for proper functioning of the immune system.
Its role is especially invaluable in the immune response as
lymphatic vessels enable leukocytes trafﬁcking and transport
of Ags and antigen-presenting cells (APCs) from the inter-
stitium to the lymph nodes, where they communicate with
naive lymphocytes. Until recently, the role of lymphatic
endothelium in immune response modulation was underes-
timated. It was thought that LECs’ function was restricted
only to the passive transport of immune cells and Ags.8
Conversely, it was shown that interstitial pressure and ﬂuid
ﬂow can activate LECs, leading to increase of ﬂuid and sol-
ute permeability, uptake and expression of adhesion mole-
cules required for immune cell migration.9 Furthermore,
current data suggest that LECs suppress dendritic cells
(DCs) maturation and further priming of CD8C T cells,
express components of antigen-presenting machinery, major
histocompatibility complex (MHC) class I and II molecules,
and may be signiﬁcant contributors to peripheral toler-
ance.10 Lately, Swartz group provided data suggesting that
LECs can constantly uptake and cross-present exogenous
Ags to CD8C T cells, under normal conditions, implying
the contribution of LECs in sustaining of CD8C T-cell toler-
ance to exogenous Ags present in the lymph.8
The lymphatic system plays an important role not only in
physiological but also in pathological conditions. The ﬂuid pro-
duction reaches up to two-thirds of the total volume of intersti-
tial ﬂuid every day. 11 Hence, any dysregulation of extracellular
ﬂuid balance, caused by insufﬁcient lymphatic vessel function,
leads to interstitial accumulation of ﬂuid and to lymphedema.
Additionally, a high-protein edema ﬂuid triggers an inﬂamma-
tory reaction, a subsequent ﬁbrosis, an adipose tissue augmen-
tation, an impaired immune response and wound healing.12
Moreover, during the inﬂammation, the gene expression proﬁle
of LECs is changed and the enhancement of C-C chemokine
receptor type 7 (CCR7)-positive DCs migration to lymphatic
vessels is mainly induced by increased secretion of a CCL21
chemokine.13
The tumor lymphatic vessels development
Recent research has deﬁned a tumor lymphangiogenesis as a
multifactorial process occurring due to the interactions between
tumor, endothelial and immune cells. These cells are the source
of protein factors that lead to LECs proliferation, migration
and vessels development. Due to a high-interstitial ﬂuid pres-
sure of most solid tumors, the lymphatic vessels in the tumor
mass are collapsed and have a limited functionality.9 Thus, they
are unable to transport cancer cells to distant organs and their
role has remained unclear, whereas lymphatics at the tumor
margin (peritumoral) facilitate the spread of cancer cells
(Fig. 1A).14
Tumor cells and tumor-inﬁltrating myeloid cells stimulate
direct formation of peritumoral lymphatic vessels via secretion
of IL-10, VEGF, TGF-b and PGE2 (Fig. 1B).15 However, the
central role in the embryonic and postnatal lymphatic forma-
tion is played by VEGFR-3, that is phosphorylated through the
interaction with secreted proteins: VEGF-C and VEGF-D. Nev-
ertheless, the lymphangiogenesis can be additionally initiated
by the activation of multiple types of receptor tyrosine kinases
such as VEGFR-2, insulin-like growth factor receptor, ﬁbro-
blast growth factor receptor 3 and angiopoietin receptors (Tie1
and Tie2). However, in view of the fact that tumor cells as well
as tumor-associated cells (ﬁbroblasts, immune cells) can over-
express VEGF-C, the VEGF-C-VEGFR-3 pathway has been so
far best described.16 The overexpression of VEGF genes seems
to be related directly to conditions of tumor environment. The
physiological environment of even microscopic tumors can be
characterized by high-interstitial pressure and hypoxia that
promote tumor growth and metastatic dissemination. The cor-
relation between hypoxia-inducible transcription factor (HIF-
1) and lymphangiogenesis was extensively studied.17 HIF-1 was
shown to stimulate transcription of important lymphangio-
genic factors: platelet derived growth factor B, Prox-1 and
SOX18. 18,19
However, it seems that hypoxia can augment the VEGF-C
protein levels also via a HIF-1 independent effect on VEGF-C
IRES-dependent initiation of translation. Moreover, this hyp-
oxia-induced switching from cap-dependent to IRES-depen-
dent VEGF-C translation was even higher in tumor cells that
had metastasized to the lymph nodes compared to tumor cells
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that were present in the primary tumor.20 These results are in
line with the pre-clinical studies on melanoma xenografts
showing that lymph nodes metastases correlate with the size of
hypoxic tissue fraction in the center of tumor as well as micro-
vascular density in the tumor periphery.21 Interestingly,
VEGFR-3 and VEGF-C expressed by metastatic tumor cells,
acts as autocrine stimulation mechanisms that may induce
tumor cells proliferation and invasiveness.22 Therefore, much
focus has been placed lately on VEGF-C implication in the lym-
phangiogenesis and tumorigenesis. In addition, there are data
indicating the role of pro-inﬂammatory TNF-a-TNFR1 signal-
ing pathway in the VEGF-C-induced lymphangiogenesis. TNF-
a stimulates LECs migration and morphological changes in a
VEGFR-3-independent manner. The downregulation of TNF-
a expression in ovarian tumors restrains lymphangiogenesis
and lymphatic metastasis. However, the blocking of VEGFR-3
still suppresses TNF-a-induced lymphatic metastasis.23
Another, newly described secreted protein, involved in the
process of tumor lymphangiogenesis is transforming growth
factor-b-induced protein (TGFBIp). Tumors expressing
TGFBIp develop more metastases via induction of LECs migra-
tion and tube formation as well as increase of lymphatic vessels
permeability.24 Interestingly, the TGFBIp-induced effect on
tumor dissemination can be abolished by lithium treatment,
that suppress the metastatic potential of colon cancer without
affecting the growth rate of tumor cells.25
The tumor-generated unique conditions of draining lymph
nodes, promoting metastases
It has been evident that cancer cells coordinate the pre-metastatic
niche formation through the secretion of a variety of cytokines,
enzymes and growth factors 26 Pre-treatment of animals with
tumor-conditioned media (TCM) not only increases lymphan-
giogenesis in draining lymph nodes and peripheral areas of
tumors but also accelerates metastasis of MDA-MB-231 and
Figure 1. (A) The lymphatic vessel in normal and mouse melanoma tumor tissue. Left. In normal skin, basement membrane-supported lymphatic vessels (L) can be mor-
phologically distinguished after identiﬁcation of intravascular valves (V) from blood capillaries (c) and adipocytes (F). Normal tissue is also free from tenascin C, extracellu-
lar matrix characteristic for tumor remodeled tissue. Middle. At the tumor margin, new extracellular matrix is deposited and pre-existing lymphatic (L) and blood vessels
(BV) are remodeled. Also, new, poorly organized vessels are formed (nL). Right. In the center of the tumor, deposition of new matrix paralleled the loss of organized tissue
architecture with large tortuous granulation tissue-like blood (c) vessels and a collapse of lymphatics. (B) The overview of LECs, tumor and tumor-associated immune cells’
interactions during tumor lymphangiogenesis and lymphatic vessels enlargement. Secretion of a variety of cytokines and growth factors mobilize tumor cells as well as
dendritic cells to get inside the initial lymphatic vessels. (C) COX-2 increases level of prostaglandin receptor (EP2) and enhances expression of VEGF-C, CCR7 as well as
CCL21. Binding of VEGFR-3, Tie1/2 and TNFR1 ligands induces LECs proliferation and capability of tube formation.
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SUM-149 in mammary fat pad xenografts models.27 Moreover, it
is suggested that in lymph nodes lymphangiogenesis occurs even
before the arrival of tumor cells and leads to the formation of the
pre-metastatic niche. Interestingly, tumor cells may inﬂuence the
gene expression proﬁle of LECs. In rat model of gastric cancer,
the signiﬁcant differences between expression proﬁle of LECs,
from control and metastatic tumor, were detected in over 800 of
genes.28 In LECs from pre-metastatic organs, treated with TCM,
expression of CCL5 and VEGF-induced tumor cell recruitment
and colonization, is increased. Additionally, these changes in
LECs expression proﬁle were observed as a result of tumor-cell-
derived-IL-6 action through the phosphorylation of STAT3.29
Although, the role of IL-6 in cancer development has been still
controversial, multiple studies have shown that elevated level of
IL-6 correlates with a poor clinical prognosis.30 Furthermore,
high-tumor expression of IL-6 in human mammary tumors
results in mobilization of tumor-associated suppressive myeloid
cells and accelerates formation of metastases.31,32 Importantly,
induction of IL-6 expression in non-metastatic mouse mammary
tumor EMT6 cell line causes recruitment of MDSCs and tumor
cell spreads, comparable to that triggered by metastasizing 4T1
cancer cells.33
The VEGF-C-stimulated tumor lymphangiogenesis estab-
lishes and increases the efﬁcacy of communication between
tumor and lymph nodes. Moreover, initial studies suggest that
VEGF-C together with enhanced lymph ﬂow of tumor Ags
may promote a suppressive function of LECs, leading to direct
inhibition of activated CD8C T cells and induction of immune
tolerance to tumor Ags.3 Although further studies are needed
to conﬁrm these data, all these observations can indicate that
tumor cells as well as tumor-associated cells inﬂuence LECs,
which next may actively participate in formation of metastases.
Lymphatic vessels’ role in antitumor immune response
and metastases formation
Recent research has highlighted that lymphatic vessels can
actively contribute to the disease progression through
management of leukocyte accumulation and retention within
inﬂamed tissue. Moreover, it seems that lymphatic vessels actively
participate in tumor spread as well as induction of immune toler-
ance. Although, secretion of VEGF-C and VEGF-D by tumor has
been correlated with lymphatic metastases both in humans and in
animal models, the mechanism of tumor cell escape into lym-
phatic vessels has still remained unclear.34 Thus, a great deal of
interest has been focused on the elucidation of mechanism of
tumor cells interaction with LECs (Table 1).
CCR7 was one of the ﬁrst described molecules, overex-
pressed by tumor cells that increases their lymphatic-depen-
dent metastatic potential. It is suggested that CCR7 is
upregulated in many cancer cells and guide them up lym-
phatic-secreted CCL21 gradients.35 In breast cancer, the expres-
sion of CCR7 was reported to be increased by cyclooxygenase-2
(COX-2) activity via prostaglandin E2 and E4 receptors
(Fig. 1C).36 High expression of this enzyme was correlated with
lymph node metastasis, poor prognosis and short survival.37
The anti-CCR7 antibody as well as knockdown of CCR7 in
COX-2-overexpressing MDAMB-231 cells signiﬁcantly attenu-
ates the effect of migration and invasion of breast cancer cells.36
Additionally, COX-2 enhances secretion of VEGF-C, that in
turn increases expression of CCR7 ligand, and CCL21 by LECs
as well as development of new lymphatic vessels.38 Tumor cells
also secrete CCR7 ligands to generate autologous gradients of
CCL19/21 chemokines that promote their migration toward
functional lymphatics.39 The selective presentation of CCR7
ligands on LECs can be explained by the expression of non-typ-
ical chemokine receptor D6. Due to the expression of D6, only
cells that are CCR7 positive (e.g., mature DCs) are able to
migrate to lymph nodes.40 However, D6 expressed by tumor
cells, was shown to inhibit the proliferation of tumor cells and
was negatively correlated with prognosis in breast cancer.41
Another chemokine receptor involved in tumor cells spread
through lymphatic vessels is CCR4. CXCL12 through CCR4
leads to actin polymerization and pseudopodia formation of
breast tumor cells and have a signiﬁcant inﬂuence on metastasis
to regional lymph nodes and lungs.42
Table 1. Molecules potentially involved in tumor cells trafﬁcking through the lymphatic vessels.
Molecule involved
in cell migration
Role in leucocytes trafﬁcking
by lymphatic vessels
Expression on
tumor cells
Inﬂuence on
tumor progression
CCR7 Upregulated CCR7 during activation and
maturation of DCs to respond to
lymphatic-secreted CCL21 and elicits
directional migration62
Melanoma, colorectal, mammary, gastric,
non-small cell lung, head and neck
cancers, thyroid and squama cell
carcinomas42,63
Expression is correlated with lymph node
metastasis.
CCR4 Selectively expressed on Th2 cells and
regulatory T cells
Breast, lung, gastric cancer 64 Expression is associated with lung and lymph
nodes metastasis. In breast cancer,
correlated with HER2 positive tumors and
poor prognosis
ICAM-1 ICAM-1 knockout mice have defects in lymph
node recruitment of DCs43
Melanoma, breast cancer, gastric cancer,
esophageal cancer, colorectal
carcinoma65
The results are controversial. In some cases
ICAM-1 plays a major role in invasion of
cancerous cells while in others decreased
expression inhibits formation of
metastases66
COX-2 COX-2 plays an important role in leucocytes
migration and adhesion, likely by
modulating p110g PI3K–mediated cell
signaling67
Breast cancer, esophageal cancer
pancreatic cancer, various colorectal
tumors, adenocarcinoma, prostate and
bladder cancers68
Upregulates CCR7 via EP2/EP4 receptor
signaling pathways and enhances lymphatic
metastasis
CD99 Involved in transmigration of monocytes,
neutrophils, lymphocytes and DCs
Ewing sarcoma, synovial sarcoma and low-
grade ﬁbromyxoid sarcoma69
Knocking down CD99 in Ewing sarcoma
reduces tumor ability to form metastases
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Although the chemokine-dependent migration mechanism of
tumor cells appears to be similar to those used by DCs, this simi-
larity to DCs cannot be established as a rule for other molecules.
For example ICAM-1 promotes the exit of leukocytes from tissue
to lymphatics.43 However, in case of tumor, the role of adhesion
molecules in metastatic dissemination has not been yet fully
understood. In melanoma, the high expression of ICAM-1 corre-
lates with the risk of metastasis, while breast cancer patients with
CAMs-positive tumors have a better prognosis.44 Nevertheless, it
is probable that some molecules like CD99 may be involved in
migration of leucocytes as well as tumor cells. CD99 has been
described as a transmigration mediator of monocytes, neutro-
phils, lymphocytes and DCs.45 The results with anti-CD99 anti-
bodies suggest a homophilic interaction between CD99 on the
leukocytes and CD99 on the endothelial cells.46 Interestingly, the
truncated isoform of CD99 enhances migration and metastasis
ability of cancer cells, while the full length of CD99 acts as an
onco-suppressor in a wider group of tumors.47 However, the
direct mechanism of tumor cells and LECs interaction mediated
by CD99 has not been yet investigated.
The anti-lymphangiogenic therapies
Monoclonal antibodies and recombinant proteins
Angiogenesis and lymphangiogenesis play a pivotal role in
tumor cells growth and dissemination, therefore, factors
involved in these processes are potential targets in antitumor
therapies. Since VEGF-C/VEGF-D-VEGFR-3 signaling axis is
the most prominent in lymphangiogenesis, neutralization of
this pathway in metastatic disease is provided with either anti-
VEGF or anti-VEGFR antibodies or soluble form of VEGF
receptor—sVEGFR-3. Interestingly, VEGFR-3 and VEGFR-2
together promote proliferation and migration of LECs, there-
fore simultaneously blocking both of the receptors seems to be
more effective in inhibition of peritumoral lymphangiogenesis
than single anti-VEGFR treatment (Table 2). Bevacizumab, an
anti-VEGF antibody, is applied in the treatment of colon, non-
small cell lung, kidney and ovarian cancer. Moreover, there are
some ongoing clinical trials using bevacizumab in combination
with different drugs, such as dexamethasone or VGX-100.
VGX-100 is an anti-VEGF-C antibody, which is currently in
phase I of clinical trials.48 However, in the mentioned com-
bined therapies, VEGF-D is still active and may induce lym-
phatic vessels formation, therefore these therapies only
partially block peritumoral lymphangiogenesis. Another agent
with promising effect in pre-clinical studies is AMG-386 (Tre-
bananib) an Angiopoietin-1/2-neutralizing peptibody, consist-
ing of Ang-binding sequence fused with Fc region of antibody.
It prevents Ang1/2 binding to Tie-2 receptor, therefore inhibits
the growth of tumor in mouse xenograft models and currently
is in phase III of clinical trials in ovarian cancer treatment.49
Moreover, AMG-386 is under current investigation in glioblas-
toma therapy combined with bevacizumab, however this study
has not been completed yet.50 There are some interesting
results indicating that sVEGFR-3 poses soluble extracellular
ligand-binding domain, able to trap VEGF-C and leads to its
inactivation, what results in inhibition of lymphangiogenesis.
Also, ramucirumab, the fully human monoclonal antibody that
binds to VEGFR-2 inhibits not only angiogenesis but may
affect lymphangiogenesis. 51
Chemotherapy
Another group of antitumor lymphangiogenesis drugs are
small molecule receptor tyrosine kinase inhibitors targeting
VEGFR-3 including regorafenib used in the treatment of meta-
static colorectal cancer and gastrointestinal stromal tumors and
axitinib applied in renal cell carcinoma therapy. A promising
choice for anti-lymphangiogenic therapy is lenalidomide
(LEN). This immunomodulatory agent currently is used in the
treatment of multiple myeloma, transfusion-dependent
Table 2. Overview of lymphangiogenesis inhibitors investigated in pre-clinical studies.
Drug name Molecular target Treatment Mechanism of action Outcome
Soluble VEGFR-370 VEGF-C Pre-clinical studies in
endometrial cancer model
Inhibits lymphatic endothelial cell growth
in vitro
Suppresses in vivo lymph node
and lung metastasis
Canstatin71 Ang1/Ang2 Pre-clinical studies in colon
carcinoma model
Reduces tumor blood and lymphatic
vessel densities
Reduces ﬁnal volume and weight
of tumors
Endostatin72 VEGFR-3 Pre-clinical Causes inhibition of bFGF-induced corneal
angiogenesis and lymphangiogenesis
—
16K hPRL73 VEGFR-3 Pre-clinical studies in
melanoma model
Induces apoptosis and inhibits
proliferation, migration and tube
formation of human dermal lymphatic
microvascular endothelial cells
Prevents lymphatic metastasis
SAR13167574 VEGFR-3 Pre-clinical studies in breast
cancer model
Reduces TAM inﬁltration Reduces lymph node and lung
metastasis
cVE-19975 VEGF-D Pre-clinical studies in
neuroblastoma model
Inhibits lymphangiogenesis Prevents lymphatic metastasis of
neuroblastoma
Nrp276 Semaphorin Pre-clinical studies in breast
cancer model
Inhibits VEGF-C-induced phosphorylation
of VEGFR-3, ERK1/2, and AKT
Tumor cells expressing sema3C
contained a lower concentration
of lymph vessels and form lymph
nodes metastasis much less
effectively
Biomimetic
peptide SP201253
c-MET Pre-clinical studies in breast
cancer model
Inhibits blood and lymphatic endothelial
cell viability, migration, adhesion and
tube formation
Inhibits lymphangiogenesis in
primary tumors
Rapamycin77 mTOR Pre-clinical studies in head and
neck cancer model
Inhibits lymphangiogenesis Prevents dissemination to the
cervical lymph nodes
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myelodysplastic syndrome and mantle cell lymphoma. In LECs,
LEN is shown to reduce levels of PROX-1 factor, podoplanin
and VEGFR-3. Several studies indicate that LEN affects not
only LECs but also tumor-associated macrophages (TAMs),
which are primarily responsible for the secretion of VEGF-C.
Additionally, LEN triggers various effects on the immune sys-
tem, which may contribute to its therapeutic outcome. It stimu-
lates CD4C and CD8C T lymphocytes and also increases the
expression of IL-2 and IFNg.52
Novel anti-lymphatic agent, collagen IV biomimetic peptide
(SP2012), inhibits metastases to lungs in breast cancer tumor
xenograft model and leads to LECs apoptosis.53 Moreover,
other well-known kinase inhibitors including sorafenib, suniti-
nib and pazopanib are already approved for the treatment of
various cancer by Food and Drug Administration (Table 3).
These drugs, well known for their anti-angiogegenic action,
also prevent phosphorylation of VEGFR-3, leading to lym-
phangiogenesis inhibition.54,55
All these experimental and clinical studies highlighted the crit-
ical role of lymphatic vasculature in tumor metastatic spreading
and point them as antitumor therapies target. Although lym-
phatic vessels are an important element of human immune sys-
tem function, little is known so far about the impact of lymphatic
destruction on immune response to cancer cells.
Photodynamic therapy as a new anti-lymphatic approach
Recently described approach used to damage lymphatic vessels is
PDT. PDT is a light-based therapeutic modality approved for the
treatment of various solid tumors as well as non-oncological con-
ditions such as age macular degeneration (AMD). In the clinical
settings, PDT procedure requires administration of a photosensi-
tizing drug, that selectively accumulates in the tumor tissue, and
irradiation of the lesion with a visible light of an appropriate
wavelength.56 Light-excited photosensitizer transfers its energy to
the molecular oxygen, leading to formation of reactive oxygen
species. Antitumor effects of PDT result from direct tumor dam-
age, collapse of tumor vasculature and induction of antitumor
immune response.57 Antivascular effect of PDT has been exten-
sively studied during the past decades, whereas anti-lymphatic
action of PDT is a recently described phenomenon. While pre-
existing lymphatic vessels cannot be eradicated with anti-lym-
phangiogenic agents, PDT can be applied for the destruction of
even pre-existing tumor lymphatic vessels. Tammela et al. have
been the ﬁrst to publish that verteporﬁn-PDT can damage
tumor-associated lymphatic vessels in mice and pigs. Moreover,
PDT of tumor lymphatic vasculature led to the eradication of
intra-lymphatic tumor cells and prevented metastasis of mouse
melanoma cells and subsequent recurrence. Interestingly, Tam-
mela et al. also have shown that combination treatment of PDT
and AdVEGFR-3-Ig reduces the surface area of peritumoral lym-
phatic capillaries when compared with single treatment.58 Fur-
thermore, as PDT is an established procedure in various
ophthalmological diseases such as AMD, Bucher et al. have used
PDT to induce regression of corneal lymphatic vessels without
affecting blood vessels inmouse model.
In our previous study, we have identiﬁed the optimal condi-
tions to selectively close lymphatic collecting vessels without
Table 3. Overview of lymphangiogenesis inhibitors investigated in clinical studies.
Drug name Molecular target As a monotherapy As a combined therapy
VGX-100 VEGF-C — With bevacizumab – Phase I ongoing (NCT01514123) in
treatment of advanced solid tumors
Lenalidomide VEGF-C Lenalidomide is used in pre-clinical studies to inhibit growth of peritumoral lymphatic vessels
Bevacizumab VEGF Bevacizumab is an inhibitor of angiogenesis studied in various pre-clinical trials as anti-lymphangiogenic drug.
Approved for various treatment: breast, lung, colorectal, renal and brain cancer
AMG-386
(Trebananib)
Ang1/Ang2 Treatment of endometrial adenocarcinoma – Phase II
ongoing (NCT01210222).
Used in the treatment of renal cell carcinoma with
sorafenib – Phase II completed (NCT00467025). No
data have been published so far
Treatment of advanced solid tumors – Phase I completed
(NCT00102830). No data have been published so far
Used in the treatment of renal cell carcinoma with
sunitinib – Phase II ongoing (NCT00853372)
MEDI3617 Ang1/Ang2 — Used in treatment of melanoma with tremelimumab –
Phase I ongoing (NCT02141542).
Used in the treatment of advanced solid tumors with
bevacizumab/paclitaxel/carboplatin/gemcitabine –
Phase I completed (NCT01248949). No data have
been published so far
CVX-060 Ang1/Ang2 Treatment of advanced solid tumors – Phase I completed
(NCT00879684). 0.3, 1, 3, 6, 12, 15 mg/kg of b.w.
intravenous infusion in Stage 1 and 15 mg/kg of
b.w. intravenous infusion in Stage 2, administered
once-weekly in a 4-week cycle
—
Sorafenib VEGFR-3 Sorafenib inhibits VEGFR-2 and VEGFR-3, blocks proliferation of different tumor cells and inhibits tumor
lymphangiogenesis.78 Was approved for renal cell carcinoma and hepatocellular carcinoma treatment.
Sunitinib VEGFR-3 In pre-clinical studies, sunitinib blocked VEGFR-2 and VEGFR-3 phosphorylation induced by VEGF-C or VEGF-D and
inhibited LECs proliferation and migration.79 Was clinically approved for renal cell carcinoma and gastrointestinal
stromal tumor treatment
Axitinib VEGFR-3 In pre-clinical studies used as VEGFR-3 inhibitor.55 Approved for renal cell carcinoma treatment
Regorafenib VEGFR-3 Regorafenib is used in pre-clinical studies to inhibit VEGFR-2 and VEGFR-3 autophosphorylation, VEGFR-3 intracellular
signaling and to block LECs migration.80
Pazopanib VEGFR-2/ VEGFR-3 Pazopanib exert anti-angiogenic and anti-lymphangiogenic potential in pre-clinical studies as VEGFR-2 and VEGFR-3
inhibitor.55 In clinical studies is use in combination with bevacizumab. Approved for renal cell carcinoma treatment
IMC-3C5 VEGFR-3 Treatment of neoplasma – Phase I completed
(NCT01288989). No data have been published so far
—
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injuring the blood vasculature in a mouse ear dermis.59 We
have shown that PDT selectively ablates lymphatic vessels and
subsequently leads to closure of lymphatic drainage in a partic-
ular region. According to our recent results, both apoptosis and
autophagy are involved in cell death induced by verteporﬁn-
PDT in LECs.60 In addition to Tammela studies presenting that
PDT-damaged lymphatic vessels regrowth after stimulation
with VEGF-C, we have shown that lymphatic vessels eventually
regenerate, without any additional treatment, by recanalization
of blocked collectors leading to restoration of lymphatic drain-
age.58,59 Therefore, in order to avoid tumor metastasis and
further relapse, treatment combining PDT with anti-lymphan-
giogenic agents seems to be rational. Such combination therapy
would be a promising approach as, according to current litera-
ture, there are several known pharmacological inhibitors of
lymphangiogenesis as well as it is possible to obtain recombi-
nant proteins able to suppress formation of lymphatic
vasculature.
However, we would like to emphasize an undiscussed prob-
lem concerning anti-lymphangiogenic therapies’ inﬂuence on
development of speciﬁc antitumor immune response. Since
Burnet and Thomas extended “immune surveillance hypothe-
sis,” suggesting that cancer cells are recognized as “foreign” by
the immune system, various immune therapies have been
extensively studied. Therefore, new effective therapies, stimu-
lating immune system and overcoming tumor suppression,
become available including, exciting recent developments,
immune checkpoint blockade.61 PDT is also thought to be an
immune therapy as it can induce strong local inﬂammatory
reaction that under some unique circumstances and in combi-
nation with immune-modulating drugs can lead to the develop-
ment of systemic antitumor immune response and the
formation of memory responses.57 A prolonged damage of
tumor lymphatic vasculature may totally abrogate immune cell
trafﬁcking from the tumor to the draining lymph nodes and
can subsequently lead to impaired development of antitumor
immune response (unpublished results). Thus, we speculate
that, even though anti-lymphangiogenic therapies can over-
come tumor tolerance and prevent metastasis, it may affect
antitumor immune response leading to poor PDT outcome.
Conclusions
In the light of the latest ﬁndings, the lymphatic vessels are not
only passive channels but also can participate in the develop-
ment of antitumor immune response. It is becoming clear that
the process of cells’ entry into the lymphatic vessels requires
active and highly complex interactions with LECs. However, in
contrast to blood vessels the mechanisms of tumor cell intrava-
sation has not been well described. Hence, it is not known what
type of junctions are preferred between tumor cell interactions
and whether the initial or/and collecting vessels are the gates
for metastatic cells entry. Therefore, to better understand the
molecular control of immune and tumor cells interaction with
LECs, further research is warranted.
The latest discoveries have demonstrated the potential of
novel therapeutic strategies to prevent formation of tumor
metastases. As we discussed here, the VEGF-C-stimulated
tumor lymphangiogenesis may have important bearing on
formation of pre-metastatic niche in draining lymph nodes,
and promotes progression and dissemination of tumor cells.
Nevertheless, the lymphatic vessels’ role in the process of anti-
gen presentation and antitumor adaptive immune response
development should not be diminished, especially in the light
of recently described effective immunotherapies. Thus, the cur-
rently generated inhibitors of VEGF-C-VEGFR-3 pathway are
probably just the beginning of therapies modulating lymphatic
function and hopefully the nearest future will bring great
advances in this ﬁeld.
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